According to DelveInsight's analysis, the growth of the FAP inhibitor market is expected to be primarily driven by the anticipated launch of several emerging therapies such as [18F] FAPI-74, [68Ga] FAPI-46, AZD2389, BXCL701, AVA6000, and others targeting a range of indications.
LAS VEGAS, Aug 7, 2025 /PRNewswire/ -- DelveInsight's FAP Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as NSCLC, Ovarian cancer, Pancreatic cancer, Metastatic colorectal cancer, Prostate cancer, Triple-negative breast cancer, Soft tissue sarcoma, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging FAP inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2040, segmented into 7MM.
Key Takeaways from the FAP Inhibitors Market Report
- As per DelveInsight's analysis, the total market size of FAP inhibitors in the 7MM is expected to surge significantly by 2040.
- The report provides the total potential number of patients in the indications, such as NSCLC, Ovarian cancer, Pancreatic cancer, Metastatic colorectal cancer, Prostate cancer, Triple-negative breast cancer, Soft tissue sarcoma, and others.
- Leading FAP inhibitor companies, such as SOFIE, BioXcel, OnkosXcel, AstraZeneca, Avacta, and others, are developing novel FAP inhibitors that can be available in the FAP inhibitors market in the coming years.
- Some of the key FAP inhibitors in the pipeline include [18F]FAPI-74, [68Ga]FAPI-46, BXCL701, AZD 2389, AVA6000, and others.
- In March 2025, Avacta announced promising early efficacy and safety data for AVA6000 in the Phase Ia Dose Escalation and ongoing enrollment in the Phase Ib Expansion Cohorts.
- In February 2024, BioXcel Therapeutics received US FDA Fast Track Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for the treatment of patients with metastatic small cell neuroendocrine prostate cancer (SCNC) with progression on chemotherapy and no evidence of microsatellite instability.
Discover which indication is expected to grab the major FAP inhibitors market share @ FAP Inhibitors Market Report
FAP Inhibitors Market Dynamics
The FAP inhibitors market is gaining momentum as the understanding of FAP's role in various pathological conditions, particularly cancer and fibrosis, continues to evolve. FAP is highly expressed in cancer-associated fibroblasts (CAFs) within the tumor microenvironment and in fibrotic tissues, but is largely absent in normal adult tissues. This selective expression profile has made FAP an attractive target for therapeutic intervention, as it allows for more precise targeting of tumor stroma or fibrotic lesions with reduced off-target effects. As a result, the FAP inhibitor landscape is witnessing increased research and development activities from both pharmaceutical companies and academic institutions.
Market growth is being fueled by multiple clinical programs evaluating FAP inhibitors in oncology, particularly in solid tumors such as pancreatic, breast, lung, and colorectal cancers. These inhibitors are being studied both as monotherapies and in combination with other agents like immune checkpoint inhibitors and chemotherapeutics. Several radiolabeled FAP inhibitors are also advancing in the diagnostics space, especially in PET imaging, offering real-time assessment of tumor burden and stromal activity. The dual diagnostic and therapeutic potential (theranostics) of FAP-targeting agents enhances their market appeal, with companies seeking to develop companion diagnostics and targeted radioligand therapies.
Despite the promising potential, challenges persist in optimizing the pharmacokinetics, safety profiles, and therapeutic windows of FAP inhibitors. Many compounds in development are still in early- to mid-stage clinical trials, and efficacy data remain limited. Additionally, while FAP overexpression is common across various tumors, patient stratification and biomarker-driven approaches will be critical for successful commercialization. Addressing these challenges through improved drug design and clinical validation will be key to unlocking the full potential of this drug class.
From a competitive standpoint, the market is moderately fragmented, with a mix of biotech startups and large pharmaceutical companies pursuing differentiated approaches. Some developers are focusing on small molecules, while others are leveraging antibody-drug conjugates (ADCs), bispecific antibodies, or FAP-targeted radiopharmaceuticals. Strategic collaborations, licensing deals, and academic partnerships are becoming common, as companies seek to access novel platforms and reduce development risk. This dynamic landscape suggests significant potential for innovation, particularly in niche indications where conventional therapies have limited efficacy.
In the coming years, the FAP inhibitors market is expected to benefit from growing interest in tumor microenvironment modulation, expanding applications in fibrotic diseases, and increased investment in precision medicine. Regulatory pathways for novel cancer and fibrosis therapeutics continue to evolve, potentially accelerating time-to-market for promising FAP-targeted agents. With no approved therapies currently available, the first entrants into the market stand to capture substantial value, especially if they demonstrate meaningful clinical benefit in underserved patient populations.
FAP Inhibitors Treatment Market
FAPI belongs to a novel class of tracers with emerging roles in cancer diagnosis and therapy. Clinical trials are actively investigating the safety and efficacy of FAP inhibitors for both oncologic and fibrotic conditions, with several candidates advancing into mid-stage trials. Currently, no FAP inhibitors have received regulatory approval. While challenges remain, such as enhancing drug delivery and reducing toxicity, FAP-targeted therapies represent a promising step forward in precision treatment for cancer and fibrotic diseases. Continued research and clinical validation could position FAP inhibitors as an innovative option for patients with these complex conditions.
FAP has gained recognition as a specific biomarker for carcinoma-associated fibroblasts (CAFs) and activated fibroblasts found in tissues undergoing extracellular matrix (ECM) remodeling due to persistent inflammation, fibrosis, or tissue repair. FAPI agents have been studied extensively across multiple tumor types, in both diagnostic imaging and therapeutic applications. The tumor microenvironment (TME), predominantly consisting of ECM components like blood vessels, cytokines, growth factors, and fibroblasts, plays a central role in cancer development. Fibroblasts contribute to collagen synthesis and modulate local inflammatory and homeostatic processes. A specialized subgroup, myofibroblasts, exhibits contractile features similar to smooth muscle cells. In colorectal cancer, FAP overexpression in fibroblasts has been associated with poor prognosis, including increased lymph node involvement, tumor recurrence, angiogenesis, and decreased overall survival.
Learn more about the FAP inhibitors @ FAP Inhibitors Analysis
Key Emerging FAP Inhibitors and Companies
Key players in the FAP inhibitor market include AstraZeneca (AZD 2389), Sofie ([18F]FAPI-74; [68Ga]FAPI-46), BioXcel/OnkosXcel (BXCL701), Avacta Life Science (AVA6000), and several other companies.
A radiopharmaceutical known as [18F] FAPI-74 combines FAPI-74, a quinoline-based compound that targets fibroblast activation protein (FAP), with the chelating agent NOTA (1,4,7-triazacyclononane-N,N',N'-triacetic acid), and is labeled with the positron-emitting isotope fluorine-18. It is designed for PET imaging of tumors and cancer-associated fibroblasts (CAFs) that express FAP. After administration, FAPI-74 binds to FAP-expressing tumor cells and CAFs. These bound cells can then be visualized via PET scans. FAP is a surface protein highly expressed in many cancers and in CAFs within the tumor microenvironment (TME). A Phase II clinical trial (NCT05641896) is underway to evaluate [18F] FAPI-74 PET imaging in patients with gastrointestinal cancers. This study is multicenter, single-arm, open-label, and non-randomized.
In October 2023, SOFIE and GE HealthCare entered into a licensing agreement for the development and commercialization of [68Ga] FAPI-46 and [18F] FAPI-74. Under this deal, GE HealthCare acquired global rights to [68Ga] FAPI-46 and ex-U.S. rights to [18F] FAPI-74, while SOFIE retained U.S. rights for [18F] FAPI-74's clinical development and commercialization.
AVA6000, a prodrug of the chemotherapy agent doxorubicin, functions by inhibiting an enzyme that promotes cancer cell growth. Unlike standard doxorubicin, AVA6000 remains inactive until it reaches tumor tissue, potentially reducing side effects. It is administered intravenously.
On January 16, 2025, Avacta reported encouraging results from its Phase I trial of AVA6000. In patients with salivary gland cancer, five out of ten showed tumor shrinkage-ranging from partial to minor responses-with a disease control rate of 90%.
The anticipated launch of these emerging therapies are poised to transform the FAP inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the FAP inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about FAP inhibitors clinical trials, visit @ FAP Inhibitors Treatment
FAP Inhibitors Overview
Fibroblast activation protein (FAP) is a type II transmembrane serine protease predominantly found on activated fibroblasts, especially within the tumor microenvironment and areas of tissue remodeling. It is largely absent in healthy adult tissues but becomes markedly upregulated in more than 90% of epithelial cancers, where it plays a key role in promoting tumor progression by remodeling the extracellular matrix, supporting angiogenesis, suppressing immune responses, and aiding tumor cell invasion. Elevated levels of FAP are also observed in various fibrotic and inflammatory conditions, including liver cirrhosis, pulmonary fibrosis, rheumatoid arthritis, and during wound healing, emphasizing its broader involvement in pathological tissue remodeling.
Because of its disease-restricted expression and functional significance, FAP has gained traction as a target for diagnostic and therapeutic applications. Radiolabeled FAP inhibitors (FAPIs) have delivered strong results in PET imaging by offering high-contrast visualization of tumors and fibrotic tissues with minimal background interference. These promising outcomes have led to the development of FAP-targeted treatments such as radioligand therapies, antibody-drug conjugates, and CAR T-cell approaches designed to modulate the tumor stroma and boost anti-cancer activity.
Nevertheless, challenges remain, particularly in achieving specificity over related proteases and managing potential side effects in fibrotic conditions. Current research efforts are focused on optimizing FAPI pharmacokinetics, enhancing therapeutic effectiveness, and evaluating synergistic strategies with immunotherapies. Notably, FAP-targeted imaging and treatment approaches are expanding beyond oncology into fields like cardiology, pulmonology, and autoimmune disease, underscoring its growing importance as a biomarker and therapeutic target with the potential to transform precision medicine for both cancer and fibrotic disorders.
FAP Inhibitors Epidemiology Segmentation
The FAP inhibitors market report proffers epidemiological analysis for the study period 2020-2040 in the 7MM, segmented into:
- Total Cases in Selected Indications for FAP Inhibitor
- Total Eligible Patient Pool in Selected Indications for FAP Inhibitor
- Total Treated Cases in Selected Indications for FAP Inhibitor
FAP Inhibitors Report Metrics | Details |
Study Period | 2020-2040 |
FAP Inhibitors Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Key Indications Covered in the Report | NSCLC, Ovarian cancer, Pancreatic cancer, Metastatic colorectal cancer, Prostate cancer, Triple-negative breast cancer, Soft tissue sarcoma, and others |
Key FAP Inhibitors Companies | SOFIE, BioXcel, OnkosXcel, AstraZeneca, Avacta, and others |
Key FAP Inhibitors | [18F]FAPI-74, [68Ga]FAPI-46, BXCL701, AZD 2389, AVA6000, and others |
Scope of the FAP Inhibitors Market Report
- FAP Inhibitors Therapeutic Assessment: FAP Inhibitors' current marketed and emerging therapies
- FAP Inhibitors Market Dynamics: Conjoint Analysis of Emerging FAP Inhibitor Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, FAP Inhibitors Market Access and Reimbursement
Discover more about FAP inhibitors in development @ FAP Inhibitors Clinical Trials
Table of Contents
1. | Key Insights |
2. | Report Introduction |
3. | Executive Summary of FAP Inhibitor |
4. | Key Events |
5. | Epidemiology and Market Forecast Methodology |
6. | FAP Inhibitor Market Overview at a Glance in the 7MM |
6.1. | Market Share (%) Distribution by Therapies in 2024 |
6.2. | Market Share (%) Distribution by Therapies in 2040 |
6.3. | Market Share (%) Distribution by Indications in 2024 |
6.4. | Market Share (%) Distribution by Indications in 2040 |
7. | FAP Inhibitor: Background and Overview |
7.1. | Introduction |
7.2. | Potential of FAP Inhibitor in Different Indications |
7.3. | Clinical Applications of FAP Inhibitor |
8. | FAP Target Patient Pool |
8.1. | Key Findings |
8.2. | Assumptions and Rationale: 7MM |
8.3. | Epidemiology Scenario in the 7MM |
8.4. | Total Cases in Selected Indications for FAP Inhibitor in the 7MM |
8.5. | Total Eligible Patient Pool for FAP Inhibitor in Selected Indications in the 7MM |
8.6. | Total Treated Cases in Selected Indications for FAP Inhibitor in the 7MM |
9. | Emerging Therapies |
9.1. | Key Competitors |
9.2. | [ F]FAPI-74: SOFIE |
9.2.1. | Product Description |
9.2.2. | Other developmental activities |
9.2.3. | Clinical development |
9.2.4. | Safety and efficacy |
9.2.5. | Analyst Views |
9.3. | AVA6000: Avacta |
List to be continued in the report | |
10. | FAP Inhibitor: Seven Major Market Analysis |
10.1. | Key Findings |
10.2. | Market Outlook |
10.3. | Conjoint Analysis |
10.4. | Key Market Forecast Assumptions |
10.4.1. | Cost Assumptions and Rebates |
10.4.2. | Pricing Trends |
10.4.3. | Analogue Assessment |
10.4.4. | Launch Year and Therapy Uptakes |
10.5. | Total Market Size of FAP Inhibitor in the 7MM |
10.6. | Market Size of FAP Inhibitor by Indication in the 7MM |
10.7. | The United States |
10.8. | EU4 and the UK |
10.9. | Japan |
11. | Market Access and Reimbursement |
12. | SWOT Analysis |
13. | KOL Views |
14. | Unmet Needs |
15. | Bibliography |
16. | Report Methodology |
Related Reports
Prostate Cancer Market
Prostate Cancer Market Insights, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including Janssen Research and Development, Sanofi, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech and DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others.
Non-Small Cell Lung Cancer Market
Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including AstraZeneca, Boehringer Ingelheim, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent, among others.
Metastatic Colorectal Cancer Market
Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic colorectal cancer companies, including Johnson & Johnson Innovative Medicine, Shanghai Henlius Biotech, Inspirna, Treos Bio, Cardiff Oncology, Agenus, Leap Therapeutics, Arcus Biosciences, Enterome, Tizona Therapeutics, Innovative Cellular Therapeutics, among others.
Pancreatic Cancer Market
Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pancreatic cancer companies, including AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fap-inhibitors-market-analysis-across-the-7mm-key-insights-and-outlook-through-2040--delveinsight-302524071.html
